Alembic Pharma Receives Four Observations From U.S. FDA For Panelav Facility

Earlier on Monday, U.S. health regulator has conducted an inspection at it Panelav facility in Gujarat and issued Form 483 with four procedural observations according to Alembic Pharmaceuticals.

“The U.S. Food and Drug Administration has conducted an inspection at Alembic Pharmaceuticals general oral solid formulation facility located at Panelav from 9-13 March, 2020,” the drug firm said in a filing to the exchanges.
This was a scheduled inspection, and at the end of the inspection, the U.S. FDA issued a Form 483 with four procedural observations.
No particular observation is related to the data integrity or repetitive in nature.

“The company will provide comprehensive corrective action report to address each observation. The company is committed to maintaining highest quality standards that meet U.S. FDA standards,” it said.
The U.S. health regulator issues observations by means of a FDA Form 483 notifying the company’s management of objectionable conditions at the facility inspected.


Please enter your comment!
Please enter your name here